PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| AWM Accurate Wealth Management LLC Accurate Wealth Management LLC | 50,000 | $62,000 | $55,500 | -$6,500 | -10.48% |
Hui Fai Tam Caitong International Asset Management Co. Ltd. | 18 | $23.72 | $19.98 | -$3.74 | -15.77% |
| RJ Rebecca Judd Pathstone Holdings, LLC | 17,487 | $18,536 | $22,033.62 | $3,497.62 | 18.87% |
| BCG BIT Capital GmbH BIT Capital GmbH | 407,555 | $533,768.2 | $513,519.3 | -$20,248.9 | -3.79% |
| Biotechnology Industry | Healthcare Sector | David H. Mack CEO | NASDAQ (NGS) Exchange | 69353Y103 CUSIP |
| US Country | 54 Employees | - Last Dividend | - Last Split | 25 Sep 2020 IPO Date |
PMV Pharmaceuticals, Inc. is a precision oncology company engaged in the groundbreaking field of developing therapeutic solutions targeted at specific mutations responsible for cancer. The focal point of their research and development efforts lies in tackling mutations of the p53 gene, which plays a crucial role in preventing cancer formation, thereby acting as a tumor suppressor. Founded initially as PJ Pharmaceuticals, Inc., the company underwent a rebranding to PMV Pharmaceuticals, Inc. in July 2013, marking the beginning of a dedicated pursuit towards leveraging precision medicine to battle the most challenging cancers. Headquartered in Princeton, New Jersey, and established in 2013, PMV Pharmaceuticals has quickly positioned itself as a prominent player in the quest for innovative cancer treatments.